TAIWAN ETF COMPARISON
00678 vs 00878
CAPITAL NASDAQ BIOTECHNOLOGY INDEX EXCHANGE compared with Cathay MSCI Taiwan ESG Sustainability High Dividend Yield ETF.
Four ways to read this comparison
Portfolio similarity, historical return, distribution yield and annual fund cost answer different questions.
Price and return trend
Normalized returns make funds with different unit prices comparable. Switch to price mode to view actual TWD prices.
Key metrics
| Metric | 00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX EXCHANGE | 00878 Cathay MSCI Taiwan ESG Sustainability High Dividend Yield ETF |
|---|---|---|
| Latest close | TWD 42.65 | TWD 35.11 |
| Assets under management | TWD 387M | TWD 656.6B |
| Beneficiaries | 1,876 | 1,668,893 |
| Trailing 12-month distribution yield | — | 7.09% |
| Total expense ratio | — | — |
| Management fee | 0.85% | 0.30% |
| Custody fee | 0.16% | 0.04% |
Performance and risk
| Metric | 00678 | 00878 |
|---|---|---|
| 1-year return | +50.18% | +76.94% |
| 3-year return | +65.82% | +104.30% |
| 5-year return | +40.34% | +138.69% |
| 1-year volatility | 21.92% | 21.08% |
| 1-year max drawdown | -6.88% | -9.88% |
| 1-year Sharpe ratio | 2.51 | 3.25 |
Returns are price returns. Risk statistics use the available one-year price history and are shown only when sufficient observations exist.
Sector allocation
Weights are based on the latest available disclosed portfolios.
Common holdings
0 securities appear in both disclosed portfolios. Data updated Sep 18, 2026.
No data is currently available.
Holdings unique to each ETF
These securities appear in one disclosed portfolio but not the other.
| # | Security | 00678 weight |
|---|---|---|
| 1 | VRTX US · VERTEX PHARMACEUTICALS INC | 8.03% |
| 2 | AMGN US · AMGEN INC | 7.85% |
| 3 | GILD US · GILEAD SCIENCES INC | 7.82% |
| 4 | REGN US · REGENERON PHARMACEUTICALS | 5.41% |
| 5 | MRNA US · MODERNA INC | 4.16% |
| 6 | RVMD US · REVOLUTION MEDICINES INC | 2.83% |
| 7 | ILMN US · ILLUMINA INC | 2.49% |
| 8 | ALNY US · ALNYLAM PHARMACEUTICALS INC | 2.20% |
| 9 | BIIB US · BIOGEN INC | 2.15% |
| 10 | ARGX US · ARGENX SE - ADR | 1.85% |
| 11 | INSM US · INSMED INC | 1.80% |
| 12 | ROIV US · ROIVANT SCIENCES LTD | 1.79% |
| 13 | RPRX US · ROYALTY PHARMA PLC- CL A | 1.77% |
| 14 | BIB US · PROSHARES ULTRA NASD BIOTECH | 1.74% |
| 15 | INCY US · INCYTE CORP | 1.73% |
| 16 | GH US · GUARDANT HEALTH INC | 1.67% |
| 17 | UTHR US · UNITED THERAPEUTICS CORP | 1.44% |
| 18 | VTRS US · VIATRIS INC | 1.37% |
| 19 | MEDP US · MEDPACE HOLDINGS INC | 1.21% |
| 20 | NBIX US · NEUROCRINE BIOSCIENCES INC | 1.05% |
| 21 | JAZZ US · JAZZ PHARMACEUTICALS PLC | 1.02% |
| 22 | ASND US · ASCENDIS PHARMA A/S | 1.02% |
| 23 | EXEL US · EXELIXIS INC | 0.97% |
| 24 | TEM US · TEMPUS AI INC-CL A | 0.97% |
| 25 | SMMT US · SUMMIT THERAPEUTICS INC | 0.95% |
Fund profile and disclosure dates
| Metric | 00678 | 00878 |
|---|---|---|
| Issuer | Capital Investment Trust | Cathay Securities Investment Trust |
| Tracking index / benchmark | — | — |
| Listing date | Jan 16, 2017 | Jul 20, 2020 |
| Latest market date | Sep 21, 2026 | Sep 21, 2026 |
| Holdings date | Sep 17, 2026 | Sep 18, 2026 |
| Eligible stock positions | 244 | 29 |
| Premium / discount | +0.40% | -0.23% |
Switching estimate
Estimate how many units of the other ETF the current market value could purchase.
0067800878
Current market valueTWD 426.5K
Unrealized gain / lossTWD 0
Estimated 00878 units12,147
Estimated annual distribution changeTWD 30.2K
This estimate excludes brokerage fees, taxes, bid-ask spreads and intraday price movement.
Continue researching this pair
Review each ETF independently or open another published comparison.
Taiwan ETF comparison FAQ
What does portfolio overlap measure?
For each common security, ETF Info takes the smaller of the two portfolio weights and adds those amounts. A higher percentage indicates more similar disclosed stock allocation.
Are historical returns shown with distributions?
Use the label shown for each metric. The long-period return fields are based on the return dataset, while the interactive price chart shows price returns and excludes distributions.
Can the lower-fee or higher-return ETF be considered the winner?
No single metric determines suitability. Fees, risk, liquidity, tracking exposure, distributions and portfolio construction answer different questions.
How to use this comparison
Fees, historical returns and overlap answer different questions. Portfolio overlap shows how similar the latest disclosed holdings are; it does not predict future performance or account for every trading cost, tax or distribution policy.